Settled, neither admitted nor denied CA NYSE
Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing
Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.
CASE PROFILE & BENCHMARKS
- Target Issuer: Valeant Pharmaceuticals International, Inc. (CA).
- Fraud Period: January 1, 2015 to December 31, 2017.
- Reported Overstatement: $58.0M.
- Total Fines & Penalties: $45.0M.
- Maximum Incarceration: No prison sentence.
- Independent Auditor: PricewaterhouseCoopers LLP.
- Primary Schemes: channel stuffing.
- Enforcement Status: SETTLED (neither admit nor deny).
OVERSTATEMENT $58.0M USD reported
TOTAL PENALTIES $45.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2017 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR U.S. Securities and Exchange Commission CA
FORENSIC ACCOUNTING AUTOPSY & MECHANICS
HOW IT WAS DONE| Forensic Aspect | Regulatory Record & Ledger Mechanics |
|---|---|
| Accounting Mechanics | Without admitting or denying the findings, the respondents consented to orders establishing that The company manipulated its accounting records by executing schemes under channel-stuffing. Financial reports filed with market regulators contained material misstatements that distorted true financial condition. |
| Evidentiary Finding | Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels. |
| Mechanism Definition | Shipping excessive quantities of inventory to distributors or resellers ahead of real demand to prematurely recognize revenue. |
| Affected Accounts | Accounts Receivable (Asset) • Revenue (Income Statement) • Cost of Goods Sold (Income Statement) • Inventory (Asset) |
| Issuer Corporate Context | Specialty pharmaceutical roll-up that used undisclosed captive specialty pharmacy Philidor Rx Services to stuff channels and accelerate revenues. |
| Independent Auditor | PricewaterhouseCoopers LLP : Big Four accounting network sanctioned for audit failures in Satyam, Colonial Bank, Evergrande, and independence violations. |
| Primary Discovery Method | Regulatory Enforcement & Forensic Audit |
ILLUSTRATIVE GENERAL LEDGER MECHANICS (CHANNEL STUFFING)
IMPROPER VS. GAAP/IFRS TREATMENT| Improper Booked Entry | Proper GAAP / IFRS Treatment | Accounting Distortion & Mechanism |
|---|---|---|
| DR: Accounts Receivable: $10,000,000 CR: Sales Revenue: $10,000,000 | DR: Finished Goods Inventory (remains on balance sheet): $6,000,000 CR: No revenue or AR recognized until legitimate delivery and demand criteria met | Issuer books large sales at quarter end by inducing distributors to take unneeded stock under deep discounts, secret return privileges, or extended payment terms. |
FINANCIAL STATEMENT & RATIO DISTORTIONS
QUANTITATIVE SCREENING SIGNALS| Financial Metric / Ratio | Distortion Direction | Forensic Explanation |
|---|---|---|
| Days Sales Outstanding (DSO) | Increases sharply | Receivables surge because distributors cannot or do not pay for inventory they cannot sell. |
| Receivables to Revenue Ratio | Increases | Accounts receivable expands far faster than cash collections. |
| Gross Margin | Unstable or declines next period | Concessions, return allowances, or steep price cuts eventually compress margins. |
| Taxonomy | Applicable Scheme Classifications |
|---|---|
| Correlated Schemes |
CHARGED RESPONDENTS & OUTCOMES
1 NAMED PARTIES| Respondent | Role | Disposition & Judicial Outcome | Prison | Civil Penalty | O&D Bar |
|---|---|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. | ISSUER | Enforcement order and financial sanctions imposed. | None | $45.0M | No |
RED FLAGS OBSERVED PRIOR TO DISCOVERY
1 EARLY WARNING INDICATORS| Red Flag Indicator | Period Observed | Observed Forensic Anomaly | Diagnostic View |
|---|---|---|---|
| CASH FLOW TO NET INCOME DIVERGENCE | 2015 | Operating cash flow severely diverged from reported earnings | Inspect Metric → |
ENFORCEMENT ACTIONS & PRIMARY DOCKETS
PRIMARY SOURCE CITATIONS| Filing Date | Type & Docket ID | Enforcement Order & Regulatory Findings | Disposition | Primary Record |
|---|---|---|---|---|
| September 20, 2017 | foreign regulator ENF-2015-valeant | Enforcement Action: Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels. Securities & Corporate Law Compliance | neither admit nor deny | Docket Record ↗ |
TIMELINE OF EVENTS
2 CHRONOLOGICAL MILESTONES| Date | Event Category | Chronological Forensic Milestone |
|---|---|---|
| June 1, 2015 | MISSTATEMENT | Material accounting irregularities commenced. |
| September 20, 2017 | ENFORCEMENT | Regulators commenced formal proceedings. |